08/11/2025
New Drug Exposes Hidden Subtypes of Psychosis
Researchers have found that not all psychosis patients respond equally to Cobenfy, the first new schizophrenia drug mechanism in decades.
In two patient cohorts, strong improvements were seen in individuals with negative symptoms or a history of stimulant use, while those with mania or aggression responded poorly.
The results suggest that psychosis is a collection of biologically diverse conditions rather than a single disease.
This study marks an early step toward precision psychiatry, where treatment choices are guided by symptom patterns and biological differences.